Trillium Therapeutics Inc R5WP-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 3:35 PM CET
9.38quote price arrow down-0.28 (-2.90%)
52 week range
1.97 - 17.70

...

Loading . . .

KEY STATS

  • Open9.28
  • Day High9.38
  • Day Low9.28
  • Prev Close9.66
  • 52 Week High17.70
  • 52 Week High Date11/30/20
  • 52 Week Low1.97
  • 52 Week Low Date07/24/20
  • Market Cap1,343.91M
  • Shares Out100.36M
  • 10 Day Average Volume1,011.17
  • Dividend-
  • Dividend Yield-
  • Beta
  • 1 Year % Change182.53

RATIOS/PROFITABILITY

  • EPS (TTM)-2.51
  • P/E (TTM)-3.74
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Trillium Therapeutics Inc News

There is no recent news for this security.

Latest R5WP-FF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47...
Jan Skvarka Ph.D.
President
James Parsons CPA
Chief Financial Officer
Address
2488 Dunwin Dr
Mississauga, ON
L5L 1J9
Canada